Abstract 293P
Background
Cervical cancer is a global public health issue. Cisplatin-based chemoradiation is the standard treatment for locally advanced scenarios. However, the toxicity and prolonged infusion time associated with cisplatin necessitate the search for options that yield similar outcomes. The objective of this study will be to compare the effectiveness of carboplatin versus cisplatin in patients with locally advanced cervical cancer undergoing chemoradiation.
Methods
The current study is an observational, retrospective, longitudinal, and descriptive type of research. The sample consisted of 183 patients with locally advanced cervical cancer who underwent chemoradiation treatment at the National Institute of Neoplastic Diseases, Lima, Peru, in the years 2014-201.
Results
Ninety-five patients aged equal to or less than 50 years and 88 patients aged over 50 years were analyzed, corresponding to 52% and 48% of the sample, respectively. The squamous cell carcinoma subtype represented 90% of the sample (164 cases), and the most frequent stages were IIB and IIIC, at 64% and 27% respectively. The trend for complete responses was higher for cisplatin, 82% vs. 77% for carboplatin. Patients who received cisplatin experienced more adverse effects than those who received carboplatin; neutropenia, diarrhea, and vomiting were the most reported events. At a 5-year follow-up, there was a 41% reduction in the risk of recurrence for cisplatin treatment (p 0.055), with a hazard ratio for overall survival of 0.72. It was observed that those who achieved a complete response had better survival.
Conclusions
In summary, while cisplatin demonstrated greater efficacy in terms of overall survival, carboplatin stood out for its more favorable tolerance profile. This suggests that carboplatin could be a valid alternative for patients with a more delicate clinical condition who might face challenges with cisplatin-associated toxicity. These findings underscore the importance of considering both efficacy and tolerability when choosing the appropriate therapy for patients with locally advanced cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N. Valdiviezo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract